Stock Track | Insulet Plunges 12.48% in Pre-market on Q2 Earnings Miss and Cautious Outlook

Stock Track

Aug 05

Shares of Insulet (PODD) plummeted 12.48% in pre-market trading on Wednesday after the medical device company reported second-quarter 2026 results that missed profit estimates and issued a forward guidance that likely disappointed investors.

For the quarter, Insulet delivered revenue of $801.7 million, beating the Ibes estimate of $787.2 million. However, net income of $95 million fell short of the expected $101.8 million, and earnings per share came in at $1.37. Looking ahead, the company projected third-quarter revenue growth of 17.5% to 19.5%, with full-year revenue growth forecasted at 20% to 22%. It also guided for adjusted EPS growth of greater than 30% for the fiscal year.

The top-line beat was overshadowed by the bottom-line miss and the Q3 revenue growth outlook, which appears to have triggered the significant pre-market decline.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/1121912773"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1121912773\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1121912773?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-05 19:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1121912773","market":"nz","top_or_hot":-1,"title":"Stock Track | Insulet Plunges 12.48% in Pre-market on Q2 Earnings Miss and Cautious Outlook","media":"Stock Track","content":"<p>Shares of Insulet (PODD) plummeted 12.48% in pre-market trading on Wednesday after the medical device company reported second-quarter 2026 results that missed profit estimates and issued a forward guidance that likely disappointed investors.</p><p>For the quarter, Insulet delivered revenue of $801.7 million, beating the Ibes estimate of $787.2 million. However, net income of $95 million fell short of the expected $101.8 million, and earnings per share came in at $1.37. Looking ahead, the company projected third-quarter revenue growth of 17.5% to 19.5%, with full-year revenue growth forecasted at 20% to 22%. It also guided for adjusted EPS growth of greater than 30% for the fiscal year.</p><p>The top-line beat was overshadowed by the bottom-line miss and the Q3 revenue growth outlook, which appears to have triggered the significant pre-market decline.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Insulet Plunges 12.48% in Pre-market on Q2 Earnings Miss and Cautious Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Insulet Plunges 12.48% in Pre-market on Q2 Earnings Miss and Cautious Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-08-05 19:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Insulet (PODD) plummeted 12.48% in pre-market trading on Wednesday after the medical device company reported second-quarter 2026 results that missed profit estimates and issued a forward guidance that likely disappointed investors.</p><p>For the quarter, Insulet delivered revenue of $801.7 million, beating the Ibes estimate of $787.2 million. However, net income of $95 million fell short of the expected $101.8 million, and earnings per share came in at $1.37. Looking ahead, the company projected third-quarter revenue growth of 17.5% to 19.5%, with full-year revenue growth forecasted at 20% to 22%. It also guided for adjusted EPS growth of greater than 30% for the fiscal year.</p><p>The top-line beat was overshadowed by the bottom-line miss and the Q3 revenue growth outlook, which appears to have triggered the significant pre-market decline.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PODD","symbol_name":"银休特","start_time":0,"source_url":"","article_id":"1121912773","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1121912773","pubTimestamp":1785928229,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Insulet (PODD) plummeted 12.48% in pre-market trading on Wednesday after the medical device company reported second-quarter 2026 results that missed profit estimates and issued a forward...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PODD":"银休特"},"translate_title":"股票跟踪 | 因第二季度盈利未达预期和谨慎前景，Insulet 盘前暴跌 12.48%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PODD":1},"content_text":"Shares of Insulet (PODD) plummeted 12.48% in pre-market trading on Wednesday after the medical device company reported second-quarter 2026 results that missed profit estimates and issued a forward guidance that likely disappointed investors.For the quarter, Insulet delivered revenue of $801.7 million, beating the Ibes estimate of $787.2 million. However, net income of $95 million fell short of the expected $101.8 million, and earnings per share came in at $1.37. Looking ahead, the company projected third-quarter revenue growth of 17.5% to 19.5%, with full-year revenue growth forecasted at 20% to 22%. It also guided for adjusted EPS growth of greater than 30% for the fiscal year.The top-line beat was overshadowed by the bottom-line miss and the Q3 revenue growth outlook, which appears to have triggered the significant pre-market decline.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}